New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics.
This antibody was isolated from blood samples from an Ebola survivor treated at Emory University Hospital during the 2014-2016 Ebola virus outbreak, an outbreak that began in West Africa and killed more than 11,300 people.
In their new study, the researchers showed that mAb 3A6 helps block infection by binding to an important part of Ebola’s viral structure, called the “stalk.” Study collaborators at the NIH’s National Institute of Allergy and Infectious Diseases (NIAID) found that treatment with mAb 3A6 can benefit non-human primates in advanced stages of Ebola virus disease.
“This antibody offers the best protection in primates, at the lowest dose yet seen for any single antibody,” says LJI Professor, President & CEO Erica Ollmann Saphire, Ph.D., MBA, who led the recent Nature Communications study alongside John A. G. Briggs, Ph.D., of Cambridge University and the Max Planck Institute of Biochemistry; Gabriella Worwa, D.V.M., and Jens H. Kuhn, M.D., Ph.D., of NIAID; and Carl W. Davis, Ph.D., and Rafi Ahmed, Ph.D., of the Emory Vaccine Center.
The discovery that mAb 3A6 appears effective at a very low dose is also exciting. “The lower the amount of an antibody you can deliver to someone, the easier it will be to manufacture a treatment-and the lower the cost,” says study first author Kathryn Hastie, Ph.D., LJI Instructor and Director of LJI’s Center for Antibody Discovery.
How the antibody works
The key to treating Ebola virus is to find antibodies that anchor tightly to and block essential machinery of the virus. The researchers zeroed in on mAb 3A6 because it appears to target a structure on Ebola virus called the “stalk.” The stalk is an important part of the Ebola virus structure because it anchors Ebola’s glycoprotein structure (which drives entry into a host cell) to Ebola’s viral membrane.
The team spearheaded efforts to capture images of mAb 3A6 in action. The researchers used two imaging techniques, called cryoelectron tomography and x-ray crystallography, to show how mAb 3A6 binds to Ebola virus to interrupt the infection process.
The researchers found that mAb 3A6 binds to a site normally concealed by a shifting landscape of viral proteins. “There’s a dynamic movement in these proteins,” says Hastie. “They might kind of wiggle around, move back and forth, maybe lean over a little bit or go up and down.”
Antibody mAb 3A6 takes advantage of this little protein dance. It has such a strong affinity for its viral target that it can slip between the proteins, lift them up, and latch on its target.
Hastie says mAb 3A6’s ability to bind to this target is important for several reasons. First, the site is conserved across different species of Ebola virus, making antibodies that target this region an attractive component in “pan-Ebolavirus” therapeutics. Second, the new understanding of how mAb 3A6 “lifts up” proteins in the viral stalk gives scientists a clearer view of Ebola’s weaknesses. MAb 3A6 also shows us how similar antibodies against the stalks of other viruses might work as well.
This study gives us some hints for how to design vaccines that are specifically against this region of Ebola virus.”
Kathryn Hastie, Ph.D., LJI Instructor and Director of LJI’s Center for Antibody Discovery
Additional authors of the study, “Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane,” include Zhe “Jen” Li Salie, who solved the X-ray structure; Zunlong Ke, who performed the cryoelectron tomography; Lisa Evans DeWald, Sara McArdle, Ariadna Grinyó, Edgar Davidson, Sharon L. Schendel, Chitra Hariharan, Michael J. Norris, Xiaoying Yu, Chakravarthy Chennareddy, Xiaoli Xiong, Megan Heinrich, Michael R. Holbrook, Benjamin Doranz, Ian Crozier, Yoshihiro Kawaoka, Luis M. Branco, Jens H. Kuhn
This study was supported in part by the National Institute of Health’s National Institute for Allergy and Infectious Diseases (grant U19 AI142790, Contract No. HHSN272201400058C, Contract No. HHSN272200700016I, Contract No. HHSN272201800013C), DARPA (contract W31P4Q-14-1-0010), and UK Medical Research Council (grant MC_UP_1201/16), the European Research Council (ERC-CoG-648432 MEMBRANEFUSION), and the Max Planck Society.
Hastie, K. M., et al. (2025). Anti-Ebola virus mAb 3A6 protects highly viremic animals from fatal outcome via binding GP(1,2) in a position elevated from the virion membrane. Nature Communications. doi.org/10.1038/s41467-025-56452-2.
News
Popular Vitamin B3 Supplements May Help Cancer Cells Survive, Scientists Warn
A new study raises important questions about widely used NAD+ supplements, suggesting that compounds often taken to boost energy and support healthy aging may have unintended consequences in cancer treatment. Millions of Americans take [...]
Scientists Discover Cancer Tumors Are “Addicted” to This Common Antioxidant
Cancer cells may be exploiting a common antioxidant as fuel, revealing a potential weakness that future therapies could target. Cancer cells may be tapping into an unexpected energy source: an antioxidant long associated with [...]
Nanotube injector transfers cytoplasmic contents and organelles between living cells safely
Cells are not isolated units; they continuously exchange proteins, genetic material, and even entire organelles with their neighbors. Intercellular transfer influences how tissues develop, respond to stress, and repair damage. In certain cancers, for [...]
CEO of America’s largest public hospital system is ready to replace radiologists with AI
The chief executive of America’s largest public hospital system says he is prepared to start replacing radiologists with artificial intelligence in some circumstances, once the regulatory landscape catches up. Mitchell H. Katz, MD, president [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Study finds higher heart disease risk in long COVID patients
People with long COVID are at increased risk of developing cardiovascular disease, according to a new study from Karolinska Institutet published in eClinicalMedicine. The results show that the risk of conditions such as cardiac arrhythmias [...]
The Corona variant Cicada is here – we know that
Online and on social media, reports are piling up about a new Sars-Cov-2 variant that is currently on the rise: BA.3.2, also known as Cicada. That's what it's all about: The Omicron variant BA.3.2, [...]
A Simple Blood Test Could Predict Dementia Risk 25 Years Early
A single blood marker may quietly signal dementia risk decades in advance. Scientists at the University of California, San Diego, have identified a blood signal that could forecast dementia risk decades before symptoms begin. Their [...]
Sperm Get Lost in Space and Scientists Finally Know Why
Having a baby in space may be far more complicated than expected, as new research shows sperm struggle to find their way in microgravity. Starting a family beyond Earth could be more complicated than [...]
Digital Dementia – Brain fog and disassociation from being chronically online
New medical evidence, featured on 60 Minutes Australia, indicates excessive screen time is causing "digital dementia" in young Australians, with brain scans showing physical shrinkage and damage. Experts warn that high device usage (6-8 hours [...]
A new, highly mutated COVID variant called ‘Cicada’ is spreading in the US.
BA.3.2, a heavily mutated new COVID-19 variant which may be better able to escape immunity from vaccines or prior infection, is now spreading in the United States. Although COVID cases are currently low nationally, [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Ancient bacteria strain discovered in ice cave is resistant to some modern antibiotics
In the depths of Scarisoara cave in Romania sits one of the world’s biggest underground glaciers, a monumental slab of ice the size of roughly 40 Olympic swimming pools that began to form around [...]
Scientists Identify “Good” Bacteria That May Prevent Long COVID
According to the WHO, about 6% of people worldwide who get COVID-19, roughly 400 million people, later develop a long-lasting form of the illness. That shows the condition remains a significant public health challenge. In [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
RNA Recycling Extends Lifespan
Summary: Researchers discovered a biological “trash disposal” mechanism that directly controls how fast we age. While circular RNA has long been known to accumulate in cells as we get older, this study proves for the [...]
